Camrelizumab - Jiangsu Hengrui Medicine/Incyte

Drug Profile

Camrelizumab - Jiangsu Hengrui Medicine/Incyte

Alternative Names: HR-301210; INCSHR-1210; SHR-1210

Latest Information Update: 19 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Chinese PLA General Hospital; Hangzhou Cancer Hospital; Incyte Corporation; Jiangsu Hengrui Medicine Co.; Nanjing Medical University; Peking University People's Hospital
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer; Oesophageal cancer
  • Phase II/III Hepatocellular carcinoma
  • Phase II Hodgkin's disease; Liver cancer; Osteosarcoma; Pancreatic cancer; Solid tumours
  • Phase I/II Biliary cancer
  • Phase I Breast cancer; Malignant melanoma; Nasopharyngeal cancer

Most Recent Events

  • 13 Apr 2018 Jiangsu HengRui Medicine plans a phase I trial of SHR 9146 in combination with SHR 1210 for Solid tumours (Combination therapy, Late-stage disease or greater) in May 2018 (NCT03491631)
  • 03 Apr 2018 Jiangsu HengRui Medicine and The First Affiliated Hospital with Nanjing Medical University plan a phase II trial for Biliary tract cancer and Cholangiocarcinoma (Combination therapy, Late-stage disease) in China (NCT03486678)
  • 21 Mar 2018 Jiangsu HengRui Medicine plans a phase II study for Gastric Cancer (Late-stage disease; First-line therapy) in March 2018 (NCT03472365)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top